hematolog
patient
immunosuppress
caus
hematolog
diseas
treatment
usual
predict
sever
type
infect
neutropenia
predispos
sever
bacteri
infect
prolong
fungal
infect
impair
tcell
function
increas
risk
fungal
viral
infect
besid
knowledg
patient
immun
statu
local
resist
pattern
frequenc
extend
spectrum
betalactamas
esbl
produc
enterobacteriacea
methillicinresist
staphylococcu
aureu
mrsa
import
decid
empir
antimicrobi
therapi
import
diagnost
principl
immunosuppress
patient
go
bug
place
infect
use
invas
procedur
often
bronchoalveolar
lavag
bal
biopsi
prevent
infect
hematolog
patient
consist
antimicrobi
prophylaxi
prevent
exposur
infecti
agent
immun
prophylaxi
vaccin
immun
globulin
studi
antibacteri
prophylaxi
perform
fluoroquinolon
although
risk
neutropen
fever
reduc
effect
outcom
variabl
use
controversi
due
increas
rate
resist
antibacteri
prophylaxi
use
reserv
highrisk
patient
antifung
antivir
prophylaxi
regimen
discuss
section
deal
specif
pathogen
chapter
prevent
measur
describ
tabl
epidemiolog
neutropen
fever
usual
defin
singl
temperatur
measur
temperatur
sustain
period
patient
anc
common
patient
hematolog
malign
occur
patient
chemotherapyassoci
neutropenia
approxim
episod
diagnosi
establish
ie
fever
unknown
origin
fuo
wherea
clinic
document
infect
microbiolog
document
infect
diagnos
around
episod
bloodstream
infect
constitut
vast
major
microbiolog
document
infect
epidemiolog
bloodstream
infect
differ
center
gener
slight
domin
gramneg
enter
bacteria
e
coli
k
pneumonia
p
aeruginosa
gramposit
pathogen
coagulaseneg
staphylococci
viridan
streptococci
e
faecium
antimicrobi
resist
rapidli
increas
among
gramneg
gramposit
isol
importantli
extend
esbl
product
enterobacteriacea
allov
mortal
low
around
due
low
mortal
patient
fuo
patient
document
infect
report
mortal
rate
consider
higher
around
patient
lung
infiltr
sever
sepsi
patient
septic
shock
b
diagnost
care
clinic
examin
perform
daili
identifi
possibl
infect
focus
detect
clinic
deterior
focus
easili
overlook
includ
dental
infect
perian
infect
blood
cultur
taken
central
cathet
peripher
simultan
make
possibl
identifi
catheterrel
bloodstream
infect
see
section
crbsi
total
blood
volum
least
ml
ie
four
bottl
reach
accept
sensit
cultur
depend
clinic
sign
infect
possibl
specimen
includ
sputum
urin
skin
stool
sampl
clostridium
difficil
pcr
respiratori
virus
perform
sever
immunocompromis
patient
respiratori
symptom
especi
influenza
season
pcr
virus
usual
part
initi
workup
patient
respiratori
symptom
thorac
ct
scan
perform
chest
xray
meaning
neutropen
patient
low
sensit
specif
see
also
section
pneumonia
bal
perform
ct
scan
show
lung
infiltr
shown
decreas
mortal
durat
fever
avoid
patient
deterior
antimicrobi
therapi
must
chang
includ
even
broader
coverag
carbapenem
meropenem
imipenem
cilastatin
prescrib
alreadi
given
empir
antifung
therapi
initi
see
section
empir
antifung
therapi
addit
amikacin
andor
vancomycin
consid
epidemiolog
respiratori
symptom
andor
new
lung
infiltr
frequent
patient
hematolog
diseas
patient
receiv
treatment
acut
leukemia
may
affect
associ
mortal
b
etiolog
often
depend
underli
immunosuppress
epidemiolog
differ
definit
crbsi
exist
common
clinic
use
definit
growth
central
blood
cultur
least
h
peripher
blood
cultur
typhliti
potenti
seriou
complic
neutropen
patient
character
fever
abdomin
pain
thicken
cecum
adjac
ileum
b
pathogenesi
involv
intestin
damag
associ
neutropenia
mucos
follow
microbi
invas
inflamm
ulcer
c
report
incid
vari
depend
definit
intens
chemotherapi
patient
hematolog
malign
patient
aml
ultrasound
ct
scan
show
bowel
wall
thicken
neutropen
patient
fever
abdomin
pain
diagnost
e
blood
cultur
clostridium
difficil
assay
perform
antimicrobi
treatment
cover
gramneg
includ
pseudomona
aeruginosa
anaerob
institut
promptli
suitabl
option
includ
monotherapi
meropenem
imipenemcilastatin
piperacillintazobactam
combin
cefepim
metronidazol
f
transloc
candida
speci
may
occur
empir
treatmentprophylaxi
candidaact
agent
fluconazol
echinocandin
consid
g
bowel
rest
gcsf
shorten
durat
neutropenia
may
consid
evid
effect
lack
h
surgeri
avoid
unless
absolut
necessari
perfor
massiv
bleed
empir
preemptiv
antifung
therapi
epidemiolog
prolong
neutropen
fever
despit
broadspectrum
antibiot
therapi
common
empir
antifung
therapi
base
indic
lead
administr
antifung
around
one
third
neutropen
patient
howev
major
patient
invas
fungal
diseas
ifd
indiscrimin
empir
antifung
therapi
thu
expos
patient
unnecessari
potenti
harm
drug
b
incid
ifd
approxim
highrisk
patient
receiv
candidaact
prophylaxi
amlmd
patient
receiv
remissionintend
chemotherapi
patient
receiv
moldact
prophylaxi
usual
posaconazol
voriconazol
report
frequenc
breakthrough
ifd
consider
lower
empir
approach
antifung
treatment
initi
h
neutropen
fever
despit
broadspectrum
antibiot
even
sign
find
suggest
ifd
discuss
approach
expos
mani
patient
unnecessari
potenti
harm
treatment
recommend
preemptiv
approach
patient
screen
bloodplasma
two
three
time
per
week
one
biomark
often
gm
biomark
becom
posit
thorac
ct
scan
perform
infiltr
present
bal
perform
empir
antifung
therapi
start
patient
neg
ct
scan
screen
biomark
continu
antifung
start
biomark
becom
posit
procedur
thorac
ct
scan
repeat
studi
shown
approach
significantli
reduc
use
antifung
without
reduc
overal
surviv
although
frequenc
diagnos
ifd
slightli
higher
empir
arm
diagnost
approach
biomark
thorac
ct
scan
perform
highrisk
patient
neutropen
fever
day
despit
broadspectrum
antibiot
tcelldirect
antibodi
thymoglobulin
alemtuzumab
andor
prolong
treatment
highdos
corticosteroid
c
low
incid
mold
infect
may
also
given
part
integr
care
strategi
togeth
molddirect
diagnost
approach
includ
weekli
screen
biomark
period
high
risk
c
thorac
ct
scan
alway
perform
typic
find
includ
nodul
consolid
lesion
wedgeshap
infarct
halo
sign
nodul
cm
diamet
surround
groundglass
opac
reflect
hemorrhag
diagnost
bal
alway
perform
unless
contraind
tabl
sputum
sent
microscopi
cultur
e
sinc
diagnost
yield
microscopi
cultur
limit
test
develop
avail
test
weak
best
result
report
combin
two
test
galactomannan
gm
antigen
test
use
gm
constitut
part
aspergillu
fungal
wall
detect
serum
bal
csf
commerci
test
fda
approv
neutropen
hematolog
patient
sensit
around
test
serum
higher
bal
patient
receiv
moldact
treatment
sensit
significantli
reduc
aspergillusspecif
lateralflow
devic
antigen
test
perform
similar
gm
advantag
provid
test
result
within
minut
well
document
candida
infect
sensit
similar
one
gm
poor
specif
due
high
rate
falseposit
result
trueposit
test
specif
